Lupin Limited - Product Pipeline Review - 2015

  • ID: 3387887
  • Company Profile
  • 43 pages
  • Global Markets Direct
1 of 3
Lupin Limited - Product Pipeline Review - 2015

Summary

The report ‘Lupin Limited - Product Pipeline Review - 2015’, provides an overview of the Lupin Limited’s pharmaceutical research and development focus.

This report provides comprehensive information on the current therapeutic developmental pipeline of Lupin Limited’s, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with special features on late-stage and discontinued projects.

The report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles/records featured in the report undergoes periodic updates following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides brief overview of Lupin Limited including business description, key information and facts, and its locations and subsidiaries
- The report reviews current pipeline of Lupin Limited’s human therapeutic division and enlists all their major and minor projects
- The report features product description and descriptive mechanism of action for key pipeline products along with the product’s developmental history and major milestones
- Special feature on out-licensed and partnered product portfolio
- The report summarizes all the dormant and discontinued pipeline projects
- Latest company statement
- Latest news and deals relating to the Lupin Limited’s pipeline products

Reasons to buy

- Evaluate Lupin Limited’s strategic position with total access to detailed information on its product pipeline
- Assess the growth potential of Lupin Limited in its therapy areas of focus
- Identify new drug targets and therapeutic classes in the Lupin Limited’s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas
- Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps
- Develop strategic initiatives by understanding the focus areas of Lupin Limited and exploit collaboration and partnership opportunities
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Plan mergers and acquisitions effectively by identifying the most promising pipeline of Lupin Limited
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Explore the dormant and discontinued projects of Lupin Limited and identify potential opportunities in those areas
- Avoid Intellectual Property Rights related issues
READ MORE
Note: Product cover images may vary from those shown
2 of 3
List of Tables
List of Figures
Lupin Limited Snapshot
Lupin Limited Overview
Key Information
Key Facts
Lupin Limited - Research and Development Overview
Key Therapeutic Areas
Lupin Limited - Pipeline Review
Pipeline Products by Stage of Development
Pipeline Products - Monotherapy
Lupin Limited - Pipeline Products Glance
Lupin Limited - Late Stage Pipeline Products
Phase III Products/Combination Treatment Modalities
Lupin Limited - Clinical Stage Pipeline Products
Phase II Products/Combination Treatment Modalities
Phase I Products/Combination Treatment Modalities
Lupin Limited - Early Stage Pipeline Products
Preclinical Products/Combination Treatment Modalities
Discovery Products/Combination Treatment Modalities
Lupin Limited - Unknown Stage Pipeline Products
Unknown Products/Combination Treatment Modalities
Lupin Limited - Drug Profiles
Biosimilar for Cancer
Product Description
Mechanism of Action
R&D Progress
LND-101001
Product Description
Mechanism of Action
R&D Progress
LNP-1892
Product Description
Mechanism of Action
R&D Progress
Biosimilar for Inflammation
Product Description
Mechanism of Action
R&D Progress
Biosimilar for Ophthalmology
Product Description
Mechanism of Action
R&D Progress
Biosimilar for Osteoporosis
Product Description
Mechanism of Action
R&D Progress
Biosimilar for Viral Infections
Product Description
Mechanism of Action
R&D Progress
etanercept biosimilar
Product Description
Mechanism of Action
R&D Progress
Small Molecule for Autoimmune Diseases
Product Description
Mechanism of Action
R&D Progress
Small Molecule for Pain and Inflammation
Product Description
Mechanism of Action
R&D Progress
Small Molecule for Viral Infections
Product Description
Mechanism of Action
R&D Progress
Small Molecule for Cancer
Product Description
Mechanism of Action
R&D Progress
Small Molecule for Endocrine Disorders
Product Description
Mechanism of Action
R&D Progress
Lupin Limited - Pipeline Analysis
Lupin Limited - Pipeline Products by Target
Lupin Limited - Pipeline Products by Route of Administration
Lupin Limited - Pipeline Products by Molecule Type
Lupin Limited - Pipeline Products by Mechanism of Action
Lupin Limited - Recent Pipeline Updates
Lupin Limited - Dormant Projects
Lupin Limited - Company Statement
Lupin Limited - Locations And Subsidiaries
Head Office
Other Locations & Subsidiaries
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

List of Tables
Lupin Limited, Key Information
Lupin Limited, Key Facts
Lupin Limited - Pipeline by Indication, 2015
Lupin Limited - Pipeline by Stage of Development, 2015
Lupin Limited - Monotherapy Products in Pipeline, 2015
Lupin Limited - Phase III, 2015
Lupin Limited - Phase II, 2015
Lupin Limited - Phase I, 2015
Lupin Limited - Preclinical, 2015
Lupin Limited - Discovery, 2015
Lupin Limited - Unknown, 2015
Lupin Limited - Pipeline by Target, 2015
Lupin Limited - Pipeline by Route of Administration, 2015
Lupin Limited - Pipeline by Molecule Type, 2015
Lupin Limited - Pipeline Products by Mechanism of Action, 2015
Lupin Limited - Recent Pipeline Updates, 2015
Lupin Limited - Dormant Developmental Projects,2015
Lupin Limited, Other Locations
Lupin Limited, Subsidiaries

List of Figures
Lupin Limited - Pipeline by Top 10 Indication, 2015
Lupin Limited - Pipeline by Stage of Development, 2015
Lupin Limited - Monotherapy Products in Pipeline, 2015
Lupin Limited - Pipeline by Top 10 Route of Administration, 2015
Lupin Limited - Pipeline by Top 10 Molecule Type, 2015
Note: Product cover images may vary from those shown
3 of 3

Loading
LOADING...

4 of 3
Note: Product cover images may vary from those shown
Adroll
adroll